ITMCTR2000003796
Not yet recruiting
Phase 1
A randomized, double-blind, placebo-controlled study of Jieyu Xifeng Decoction in the treatment of anxiety insomnia
Shanghai Hospital of traditional Chinese Medicine0 sitesTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shanghai Hospital of traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. According to the diagnostic criteria of Western medicine for insomnia;
- •2\. According to the TCM diagnostic criteria of insomnia;
- •3\. The age is 18\-70 years old;
- •4\. PSQI score \> 11, Spiegel Sleep Scale (improved) score \> 12,HAMA score \>\= 14, and HAMA \< 30;
- •5\. No traditional Chinese medicine or western medicine was used to treat insomnia symptoms in the past month, or other drugs were taken in a short time (1 week), but no effect was found;
- •6\. Those who voluntarily participate in this clinical study, are willing to receive treatment in accordance with the prescribed course of treatment, and can sign informed consent.
Exclusion Criteria
- •1\. Patients with depression, severe anxiety, bipolar disorder, schizophrenia, aphasia and other serious, neuropsychiatric diseases, accompanied by thyroid function, hypertension, coronary heart disease and with serious heart, liver, kidney or other serious organic damage disease;
- •2\. Pregnant and lactating women;
- •3\. Subjects taking sleeping pills, antidepressants, etc.;
- •4\. Those who fail to treat according to the specified requirements, and fill in incomplete information, etc. can not accurately judge the curative effect.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agentsRheumatoid ArthritisJPRN-jRCT2080221561ovartis Pharma K.K.
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-PTYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasiaEUCTR2005-001627-11-ITYAMANOUCHI PHARMA882
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTOREEUCTR2005-001627-11-FIYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
Active, not recruiting
Phase 1
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisMedDRA version: 20.0Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-002988-18-BESanofi-Aventis Recherche & Développement508